DRNG yields 1290322.58% · ABBV yields 3.06%● Live data
📍 DRNG pulled ahead of the other in Year 1
Combined, DRNG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DRNG + ABBV for your $10,000?
Drone Guarder, Inc., an early stage security and surveillance company, focuses on commercializing a drone enhanced home security system as a turnkey solution in the United States, Canada, Europe, South Africa, and the Asia-Pacific region. The company's DroneGuarder app-based solution includes a drone, infrared camera, and Android mobile app component that takes off from a wireless charging pad once an alarm has been triggered, records video for a few seconds, processes it, and sends an alert if a threat is found, which the DroneGuarder app sends in the form of a text, image, or short recorded video if supported by the GSM network. It intends to sell its solution directly to the clients, including homes, business, or security resellers. The company was formerly known as Vopia, Inc. and changed its name to Drone Guarder, Inc. in March 2017. The company was founded in 2012 and is based in London, the United Kingdom. Drone Guarder, Inc. is a subsidiary of Gimwork Project LP.
Full DRNG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.